BioSpace News Archive

Customers can support the St. Jude mission of Finding cures. Saving children.® by donating at the register

CannaTech Sydney, Australia’s first ever medical cannabis conference, is proud to host poster presentations of ground-breaking medical cannabis research from over thirty prestigious Australian and international institutions and corporations,

The FDA grants Priority Review to medicines that have the potential to provide significant improvements in the treatment of a serious disease.

Top International Cannabis Business Leaders to Speak on Cannabis, the Fastest Growing Market in the World

Total net product sales of $3,890 million, increased 18% Y/Y

To celebrate 1 million loyalists in less than 3.5 years, Galderma will announce the winner of a consumer sweepstakes for ASPIRE members this month.

Collaboration agreement to evaluate the combination of [fam-] trastuzumab deruxtecan (DS-8201), an investigational HER2 targeting antibody drug conjugate (ADC), in combination with the checkpoint inhibitor avelumab and/or an investigational Merck KGaA, Darmstadt, Germany DNA damage response (DDR) inhibitor, in patients with HER2 expressing or mutated solid tumors.

M3 Biotechnology, a Seattle-based therapeutics company dedicated to developing, first-in-class, therapies for Alzheimer’s and Parkinson’s that are focused on regeneration, today announced the appointment of Marwan Sabbagh, M.D; Jay Kranzler, MD, PhD; and Frank Rockhold, PhD to the company’s Clinical Advisory Board.

Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the company will feature a total of six company-sponsored abstracts, including two oral presentations, at the 11th International Symposium on Hodgkin Lymphoma (ISHL), October 27-29, 2018, in Cologne, Germany.

Dr. Ways is a seasoned industry expert with over 30 years of experience in medical research and will support the Company’s objective in advancing late-stage clinical assets toward FDA approval.